From companies receiving CE marking to other companies adjusting their distribution deals, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Viveve Medical closes public offering Viveve Medical announced that it closed its underwritten public offering of 8,625,00 shares of its common stock, according to a March 22 […]
Astute Medical
Bio-Techne invests $43m, partners with Astute Medical
Life sciences research and diagnostics company Bio-Techne said this week it completed a $43 million equity investment in Astute Medical, with an option to further expand the relationship. Bio-Techne said the investment will allow it to “build a strategic foundation in diagnostics,” and that along with the investment the company will receive manufacturing rights for certain future […]
Astute Medical raises $2 million
Astute Medical raised $2 million in a new round of debt financing, according to an SEC filing posted today. San Diego-based Astute Medical develops and produces the NephroCheck, a device designed to test for acute kidney injury in patients who have suffered a serious cardiac or respiratory event. Money in the round came from 13 […]
Astute Medical raises $20m, inks China distribution deal
Astute Medical said it raised $20 million from Shanghai Fosun Pharmaceutical (SHA:600196) and inked a distribution deal with the Chinese company for its NephroCheck kidney-injury test. The multi-year deal calls for Shanghai Fosun’s Long March Medicine Science subsidiary to distribute NephroCheck on the Astute140 meter in China. NephroCheck is marketed in the U.S. by Ortho-Clinical Diagnostics. “Our strategy is to deliver […]
Astute Medical to receive up to $30M from CRG for kidney-injury test | Medtech funding for the week of October 13, 2014
FDA nod triggers $30m milestone for Astute Medical
Astute Medical said it’s in line to receive up to $30 million under a standing loan agreement from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test, and could receive an additional $10 million if it hits certain revenue milestones.
